Current Management Options for Hereditary Angioedema

@article{Bork2012CurrentMO,
  title={Current Management Options for Hereditary Angioedema},
  author={K. Bork},
  journal={Current Allergy and Asthma Reports},
  year={2012},
  volume={12},
  pages={273-280}
}
  • K. Bork
  • Published 2012
  • Medicine
  • Current Allergy and Asthma Reports
    • The aim of treatment of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency (HAE-C1-INH) is either treating acute attacks or preventing attacks by using prophylactic treatment. For treating acute attacks, plasma-derived C1 inhibitor (C1-INH) concentrates, a bradykinin B2 receptor antagonist, and a recombinant human C1-INH are available in Europe. In the United States, a plasma-derived C1-INH concentrate, a bradykinin B2 receptor antagonist, and a plasma kallikrein inhibitor have… CONTINUE READING
    View on Springer
    ncbi.nlm.nih.gov
    21 Citations
    Background Citations
    4
    Methods Citations
    2
    21 Citations
    Citation Type

    Citation Type

    Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema
    • 3
    • PDF
    Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
    • 7
    Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.
    • 28
    Acute Management of Hereditary Angioedema Attacks.
    • C. Katelaris
    • Medicine
    • Immunology and allergy clinics of North America
    • 2017
    • 5
    Current pharmacotherapy of bradykinin-mediated angioedema
    • H. Farkas
    • Medicine
    • Expert opinion on pharmacotherapy
    • 2013
    • 35
    Angiotensin-converting enzyme inhibitor-induced angioedema--a dangerous new epidemic.
    • 45
    • PDF
    Acquired complement C1 esterase inhibitor deficiency in a patient with a rare SERPING1 variant with unknown significance
    • 1
    Hereditary angioedema: what the gastroenterologist needs to know
    • 18
    • PDF
    Critical upper airway obstruction in sporadic angioedema responding to C1-esterase inhibitor
    • 2
    C1-Esterase Inhibitor: Biological Activities and Therapeutic Applications
    • 13
    • PDF

    References

    SHOWING 1-10 OF 45 REFERENCES
    Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.
    • 115
    Long-Term Prophylaxis of Hereditary Angioedema with a Pasteurized C1 Inhibitor Concentrate
    • G. A. Tallroth
    • Medicine
    • International Archives of Allergy and Immunology
    • 2010
    • 18
    Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate.
    • 288
    Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.
    • 188
    Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency.
    • 146
    Hereditary Angioedema: Long-Term Treatment with One or More Injections of C1 Inhibitor Concentrate per Week
    • K. Bork, J. Hardt
    • Medicine
    • International Archives of Allergy and Immunology
    • 2010
    • 45
    Hereditary angioedema: a current state-of-the-art review, III: mechanisms of hereditary angioedema.
    • A. Davis
    • Medicine
    • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
    • 2008
    • 62
    Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency.
    • 155
    Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.
    • 286
    Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients.
    • K. Bork, A. Bygum, J. Hardt
    • Medicine
    • Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
    • 2008
    • 167